Last update:

Medications news

Medications

Clinical trial highlights promising new treatment for intestinal worms

A new tablet combining albendazole and ivermectin is safe and more effective than albendazole alone in treating Trichuris trichiura and other soil-transmitted helminths (STH), according to a clinical trial conducted by the ...

Medications

Study reveals cost differences between Medicare Advantage and traditional Medicare patients in cancer drugs

A new study examining the use of high-cost drugs among patients with colorectal cancer and non-small cell lung cancer found those insured through Medicare Advantage received less expensive cancer drugs compared to others ...

Medications

Medicare rules may reduce prescription steering

Weill Cornell Medicine researchers have found that pharmacy benefit managers (PBMs)—organizations that negotiate access to medicines for most patients in the United States—steer patients to use their own pharmacies. However, ...

Medications

New drug for prostate cancer patients in clinical trials

Prostate cancer that has become resistant to hormone therapy could be treated using a new drug that is currently in clinical trials for ovarian and bile duct cancer, according to research published in the journal Clinical ...

Medications

Talquetamab plus teclistamab shows promise in multiple myeloma

For patients with relapsed or refractory multiple myeloma, talquetamab plus teclistamab shows response in a high percentage of patients and a higher incidence of grade 3 or 4 infections than with either therapy alone, according ...

Medications

DoxyPEP use linked to sharp decline in STI cases

A new study has found that rates of chlamydia and syphilis plummet among people prescribed doxycycline for sexually transmitted infection prevention in routine clinical care.

Medications

How legal pot may be reducing opioid prescriptions

In states where medical marijuana is legal, payments from opioid manufacturers to physicians have decreased significantly—suggesting that marijuana may be emerging as a viable alternative to opioids for pain management, ...

Medications

Diabetes drugs like Ozempic lower cancer risks: Study

A class of diabetes medications, which include the best-selling drug Ozempic, are associated with a reduced risk of certain obesity-related cancers, according to a study released Friday.

Medications

Rapid drug test to provide patients with better care

Teams at two of Melbourne's leading research and medical institutes are developing high-tech solutions to rapidly test for drugs and better treat patients presenting to hospital.

Medications

Scientists unravel life-saving effect of dexamethasone in COVID-19

Dexamethasone is one of the most important drugs in the treatment of severe COVID-19, but patients respond very differently to the therapy. Researchers at the German Center for Neurodegenerative Diseases (DZNE) and Charité—Universitätsmedizin ...

Medications

EU approves Sanofi drug for chronic lung disease

The European Union has approved Sanofi and Regeneron's blockbuster drug Dupixent for the treatment of chronic obstructive pulmonary disease (COPD), the French pharmaceutical giant said on Wednesday.

Medications

Researchers examine cancer drug guidelines and FDA approvals

Drugs for serious or life-threatening diseases can receive expedited U.S. Food and Drug Administration (FDA) review, allowing patients to receive faster access to promising new treatments. Under the expedited review pathway ...

Medications

Biden calls for lower prices of Ozempic, similar drugs

US President Joe Biden on Tuesday called on pharmaceutical giants Novo Nordisk and Eli Lilly to lower prices for diabetes and weight loss drugs such as Ozempic, saying firms must stop "ripping off the American people."

Medications

Study compares weight gain across eight common antidepressants

New evidence comparing weight gain under eight different first-line antidepressants finds that bupropion users are 15–20% less likely to gain a clinically significant amount of weight than users of sertraline, the most ...